Molecular Partners

Molecular Partners Announces Dismissal of Class Action Lawsuit

Retrieved on: 
Friday, March 1, 2024

Molecular Partners was represented by Cooley LLP in the litigation.

Key Points: 
  • Molecular Partners was represented by Cooley LLP in the litigation.
  • The original case was filed on July 12, 2022 in the U.S. District Court for the Southern District of New York.
  • On February 5, 2024, the court dismissed the amended complaint without prejudice and gave the plaintiff the opportunity to amend the complaint by February 26, 2024.
  • On February 23, 2024, plaintiff filed a stipulation of dismissal with prejudice.

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Retrieved on: 
Friday, March 1, 2024

Molecular Partners’ Chief Executive Officer Patrick Amstutz will also present at the 44th Annual Cowen Health Care Conference taking place in Boston, MA, and will participate in the Leerink Global Biopharma Conference taking place in Miami, FL along with other members of the Company’s leadership team.

Key Points: 
  • Molecular Partners’ Chief Executive Officer Patrick Amstutz will also present at the 44th Annual Cowen Health Care Conference taking place in Boston, MA, and will participate in the Leerink Global Biopharma Conference taking place in Miami, FL along with other members of the Company’s leadership team.
  • Please see details below:
    Cowen Health Care Conference Presentation Details:
    Novel Oncology Targets Corporate Panel Discussion:
    Leerink Global Biopharma Conference Participation Details:
    Full Year 2023 Results Release Date and Time:
    Full Year 2023 Conference Call Details:
    The full year 2023 results presentation will also be webcast live and will be made available on the Company’s website under the investors section .
  • The replay will be available for 90 days following the presentation.
  • In order to register for the full year 2023 conference call on March 15, 8:00 am ET / 1:00 pm CET, please dial the following numbers approximately 10 minutes before the start of the presentation.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 7, 2024

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Retrieved on: 
Friday, January 5, 2024

This agreement represents the first co-development deal for Molecular Partners and Orano Med.

Key Points: 
  • This agreement represents the first co-development deal for Molecular Partners and Orano Med.
  • Both companies are developing additional radioligand therapy candidates in partnership with other companies, with Molecular Partners having announced its first collaboration with Novartis in December 2021.
  • Under the terms of the co-development agreement, Molecular Partner’s previously disclosed RDT target DLL3 (delta-like ligand 3) will be included in the partnership with Orano Med.
  • DLL3 will be exclusively developed by Molecular Partners and Orano Med as a RDT target.

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

Retrieved on: 
Thursday, January 4, 2024

Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer.
  • At Novocure, Dr. Leupin will oversee medical affairs, medical safety, and clinical development operations as the company advances its clinical pipeline and prepares to treat an expanded patient population.
  • “It is a pleasure to welcome Dr. Leupin to Novocure as our new Chief Medical Officer,” said Asaf Danziger, Novocure’s Chief Executive Officer.
  • Dr. Leupin will assume the clinical and medical responsibilities held by Pritesh Shah, Novocure’s former Chief Growth Officer.

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Retrieved on: 
Thursday, December 14, 2023

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA.

Key Points: 
  • ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA.
  • In addition, members of Molecular Partners’ leadership team will participate in upcoming investor events in Switzerland during January 2024.

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Retrieved on: 
Sunday, December 10, 2023

These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.

Key Points: 
  • These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.
  • “We are excited to share these initial data for MP0533, where we see antileukemic activity, already at these low doses, with a favorable safety profile.
  • We look forward to the continuation of this study and evaluating the full potential of MP0533 for patients,” said Patrick Amstutz, CEO of Molecular Partners.
  • Details of the poster presenting these results from the ongoing Phase 1/2a trial of MP0533 at the 65th ASH Annual Meeting and Exposition can be found below.

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Retrieved on: 
Tuesday, November 14, 2023

The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.

Key Points: 
  • The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.
  • This conditional activation is intended to focus immune attack more specifically against tumor cells and minimize damage to healthy cells, a major challenge for current oncology drugs and development efforts.
  • The SWITCH-DARPin platform, a versatile novel DARPin design for conditionally triggering an immune cell attack only in the presence of defined tumor antigens.
  • The portfolio of RDT candidates represent a unique delivery system for radioactive payloads to solid tumors and has significantly expanded the company’s work in oncology therapeutics.

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Retrieved on: 
Friday, November 3, 2023

MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP).

Key Points: 
  • MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (TME) by anchoring to fibroblast activation protein (FAP).
  • “The encouraging results presented at SITC provide clinical evidence of MP0317-induced, tumor-targeted CD40 activation.
  • The positive results of this fully enrolled Phase 1 study in patients with refractory/relapsed tumors support continued clinical evaluation of MP0317 and potential investigation in combination studies.
  • Patients received MP0317 at doses of 0.03–10 mg/kg in every-3-weeks (Q3W) or weekly (Q1W) schedules (data cut-off 10 October 2023).

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

Retrieved on: 
Thursday, November 2, 2023

MP0533 is in development for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (AML/MDS).

Key Points: 
  • MP0533 is in development for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (AML/MDS).
  • As of data cut-off (20 July 2023) of the abstract published today, five patients across three dosing regimens had been treated.
  • The Company anticipates to present data including from the fourth dose cohort at the ASH Annual Meeting and Exposition in December this year.
  • “The data from the ASH abstract represent the beginning of an exciting and encouraging clinical journey for the MP0533 program.